SNPX
Synaptogenix
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SNPX
Synaptogenix, Inc.
A clinical-stage biopharmaceutical company that developing new therapies for neurodegenerative diseases
1185 Avenue of the Americas, 3rd Floor , New York, New York 10036
--
Synaptogenix, Inc., was incorporated in Delaware on October 31, 2012. The company is a biopharmaceutical company with product candidates in preclinical and clinical development. The Company is primarily focused on developing a product platform based on a drug candidate called Bryostatin-1, synthesized from a natural product (bryostatin) isolated from marine invertebrate organisms for the treatment of Alzheimer's disease (" AD "), which is in clinical testing.
Company Financials
EPS
SNPX has released its 2023 Q3 earnings. EPS was reported at -0.03, versus the expected 0.00, missing expectations. The chart below visualizes how SNPX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available